Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel

Citation
N. Arber et al., Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel, CANC EPID B, 8(12), 1999, pp. 1101-1105
Citations number
48
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
ISSN journal
10559965 → ACNP
Volume
8
Issue
12
Year of publication
1999
Pages
1101 - 1105
Database
ISI
SICI code
1055-9965(199912)8:12<1101:AITEOC>2.0.ZU;2-D
Abstract
Tumors of the small bowel are quite rare for unknown reasons, although they resemble colorectal tumors in many respects. The purpose of this study was to determine whether abnormalities in the expression of several cell cycle control genes are of importance in small bowel tumorigenesis by comparing a series of samples of normal mucosa, adenomatous polyps, and adenocarcinom as. The levels of cyclin D1, cyclin E, p16, p21, p27, and p53 proteins were determined by immunohistochemistry in samples of normal small bowel (n = 1 6), small bowel adenomas (n = 20), and small bowel adenocarcinomas (n = 24) , Normal small bowel mucosa expressed p27 protein, but not the other cell c ycle-related proteins. About 20% of the tumors displayed a decrease in the expression of this protein. The most frequent alteration in the tumors was an increase in the p16 protein. Increased expression of p53 was associated with tumor progression because it was overexpressed in 45% of the adenomas and 65% of the adenocarcinomas (P < 0.05), Advanced age and increased detec tion of cyclin D1 and p53 were associated with a decreased 3-year survival (P < 0.05), Cell cycle abnormalities are early and important events in the multistep process of small bowel tumorigenesis, thus resembling colorectal carcinogenesis, As in colon cancer, deregulated expression of G(1) proteins may perturb cell cycle control in benign adenomas of the small bowel and t hereby enhance tumor progression. Increased expression of cell cycle inhibi tors in tumors may serve as a defense mechanism for tumor progression.